Education
About Us
Working with TipRanks
Follow Us
Viatris (VTRS)
NASDAQ:VTRS
VTRS Stock Chart & Stats
$10.12
>-$0.01(-0.04%)
At close: 4:00 PM EST
$10.12
>-$0.01(-0.04%)
Day’s Range― - ―
52-Week Range$6.85 - $13.55
Previous CloseN/A
Volume2.11M
Average Volume (3M)8.42M
Market Cap
$11.66B
Enterprise Value$25.14B
Total Cash (Recent Filing)$975.30M
Total Debt (Recent Filing)$16.26B
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Mar 02, 2026EPS Estimate
0.54Last Dividend Ex-Date
Aug 22, 2025Dividend Yield4.58%
Share Statistics
EPS (TTM)0.67
Shares Outstanding1,151,769,900
10 Day Avg. Volume11,109,525
30 Day Avg. Volume8,423,017
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.80
Price to Sales (P/S)1.01
P/FCF Ratio7.52
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda-41.98
Forecast
1Y Price Target
$11.00Price Target Upside8.70% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth PotentialAnalyst's recommendation to initiate with BUY and $15 PT is based on the company's potential for growth and changes in leadership.
LeadershipThe direction of the company is undergoing an affirmative change under the refreshed leadership team supported by a market leading branded portfolio, a progressive generics foothold, and a robust pipeline with blockbuster potential.
Strategic PlanThe company is nearing completion of its 'Phase 1' strategic plan that includes stabilizing the base business, growing the pipeline, and reducing debt.
Bears Say
Manufacturing IssuesViatris is facing a manufacturing overhang at its Indore, India facility after receiving a Warning Letter and a US Import Ban on 11 products due to poor quality controls and inadequate handling of manufacturing errors.
Regulatory RisksRisks include regulation and pricing uncertainty, litigation, regulatory scrutiny of manufacturing compliance, and potential spillover to other facilities.
Viatris News
VTRS FAQ
What was Viatris’s price range in the past 12 months?
Viatris lowest stock price was $6.85 and its highest was $13.55 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $11.66B.
When is Viatris’s upcoming earnings report date?
Viatris’s upcoming earnings report date is Mar 02, 2026 which is in 112 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Nov 06, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.621 by $0.049.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Undervalued.
Does Viatris pay dividends?
Viatris pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 4.58%. See more information on Viatris dividends here
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.54.
How many shares outstanding does Viatris have?
Viatris has 1,151,769,900 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.67 in its last earnings report, beating expectations of $0.621. Following the earnings report the stock price went down -5.953%.
Which hedge fund is a major shareholder of Viatris?
Currently, no hedge funds are holding shares in VTRS
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.00 (8.70% Upside)
$11.00 (8.70% Upside)
Blogger Sentiment
Neutral
VTRS Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $219.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.51%
12-Months-Change
Fundamentals
Return on Equity
-21.09%
Trailing 12-Months
Asset Growth
-15.27%
Trailing 12-Months
Company Description
Viatris
Viatris (VTRS) is a global healthcare company formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. The company operates in the pharmaceutical sector, focusing on providing access to medicines across a wide range of therapeutic areas, including infectious diseases, cardiovascular health, diabetes, and oncology. Viatris offers a diverse portfolio of generic and branded medications, over-the-counter products, and biosimilars, aiming to improve patient health outcomes worldwide.
VTRS Company Deck
VTRS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strong commercial performance in certain segments and strategic advancements in R&D, offset by challenges related to the Indore facility and specific market declines. The company is actively addressing these issues and making progress in its strategic initiatives.View all VTRS earnings summariesVTRS Net sales Breakdown
62.62% Brands
37.38% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$11.00
▲(8.70% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
0.24% Insiders
27.38% Mutual Funds
0.38% Other Institutional Investors
43.59% Public Companies and Individual Investors